These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 7873457)

  • 1. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.
    Pérez Carrión R; Alberola Candel V; Calabresi F; Michel RT; Santos R; Delozier T; Goss P; Mauriac L; Feuilhade F; Freue M
    Ann Oncol; 1994; 5 Suppl 7():S19-24. PubMed ID: 7873457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formestane: effective therapy in postmenopausal women with advanced breast cancer.
    Bajetta E; Zilembo N; Buzzoni R; Noberasco C; Martinetti A; Ferrari L; Bartoli C; Sacchini V; Attili A; Lepera P
    Ann Oncol; 1994; 5 Suppl 7():S15-7. PubMed ID: 7873456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced breast cancer with formestane.
    Murray R; Pitt P
    Ann Oncol; 1994; 5 Suppl 7():S11-3. PubMed ID: 7873455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.
    Wiseman LR; Goa KL
    Drugs Aging; 1996 Oct; 9(4):292-306. PubMed ID: 8894526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formestane in the treatment of advanced postmenopausal breast cancer.
    Possinger K; Jonat W; Höffken K
    Ann Oncol; 1994; 5 Suppl 7():S7-10. PubMed ID: 7873464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK).
    Thürlimann B; Castiglione M; Hsu-Schmitz SF; Cavalli F; Bonnefoi H; Fey MF; Morant R; Löhnert T; Goldhirsch A
    Eur J Cancer; 1997 Jun; 33(7):1017-24. PubMed ID: 9376181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
    Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
    Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proper sequence of endocrine therapies in advanced breast cancer.
    Rose C
    Acta Oncol; 1996; 35 Suppl 5():44-9. PubMed ID: 9142964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer.
    Noberasco C; Bajetta E; Zilembo N; Di Leo A; Cappuzzo F; Bartoli C; Bono A; Bichisao E
    Oncology; 1995; 52(6):454-7. PubMed ID: 7478430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
    Thürlimann B; Hess D; Köberle D; Senn I; Ballabeni P; Pagani O; Perey L; Aebi S; Rochlitz C; Goldhirsch A
    Breast Cancer Res Treat; 2004 Jun; 85(3):247-54. PubMed ID: 15111763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.
    Wiseman LR; McTavish D
    Drugs; 1993 Jan; 45(1):66-84. PubMed ID: 7680986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability.
    Venturino A; Comandini D; Granetto C; Audisio RA; Castiglione F; Ross R; Repetto L
    Breast Cancer Res Treat; 2000 Aug; 62(3):217-22. PubMed ID: 11072786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formestane: an effective first-line endocrine treatment for advanced breast cancer.
    Zilembo N; Bajetta E; Noberasco C; Buzzoni R; Vicario G; Bono A; Laffranchi A; Biasi G; Dolci S; Bichisao E
    J Cancer Res Clin Oncol; 1995; 121(6):378-82. PubMed ID: 7797604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study of formestane in postmenopausal women with breast cancer.
    Joseph JK; Lim AK
    Med J Malaysia; 1998 Mar; 53(1):37-41. PubMed ID: 10968135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group.
    Bajetta E; Zilembo N; Barni S; Noberasco C; Martinetti A; Ferrari L; Schieppati G; Buzzoni R; Jirillo A; Amichetti M; D'Aprile M; Comella G; Bichisao E; Bolelli GF; Attili A; Bombardieri E
    Ann Oncol; 1997 Jul; 8(7):649-54. PubMed ID: 9296217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy.
    Harper-Wynne C; Coombes RC
    Eur J Cancer; 1999 May; 35(5):744-6. PubMed ID: 10505035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Therasse P; Palmer MJ; Pater JL
    N Engl J Med; 2003 Nov; 349(19):1793-802. PubMed ID: 14551341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
    Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
    J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.